Nathan L. Mata Insider Trading Activity
Corporate InsiderChief Scientific Officer · CIK 2013987
Nathan L. Mata has been net-selling over the last 12 months with 0 purchases and 102 sales across 1 company.
BLTE is the most-traded position with 102 trades. The largest single transaction was a sale of BLTE for $91K on Apr 15, 2026.
Performance Scorecard
Forward stock performance after each transaction by Nathan L. Mata. Buy returns measure price movement after open-market purchases; sell-avoided measures the loss avoided after open-market sales. Success rate counts trades where the insider's direction was right.
| PERIOD | AVG BUY RETURN | AVG SELL AVOIDED | SUCCESS RATE | TRADES |
|---|---|---|---|---|
| 30 days | — | +11.0% | 100% | 102 |
| 90 days | — | +6.7% | 100% | 51 |
| 120 days | — | — | — | — |
Performance based on stock price movement after each transaction date. Past results do not predict future returns. Not financial advice.
Price & Trades
Pro: Trade MarkersBLTE · BELITE BIO, INC
🔒 Subscribe to see trade entries
Pro members see exactly when Nathan L. Mata bought and sold BLTE.
Upgrade to ProRecent Trades
Showing the 50 most recent of 102 disclosed trades.
| DATE | TICKER | TYPE | SHARES | PRICE | VALUE | Δ OWNED | ROLE | FILING |
|---|---|---|---|---|---|---|---|---|
May 7, 2026 | BLTE | Sell | 3 | $154.61 | $463.83 | −25.0% | Chief Scientific Officer | |
May 7, 2026 | BLTE | Sell | 226 | $152.45 | $34K | −33.9% | Chief Scientific Officer | |
May 7, 2026 | BLTE | Sell | 428 | $153.56 | $66K | −97.3% | Chief Scientific Officer | |
May 7, 2026 | BLTE | Sell | 9 | $155.25 | $1K | −100.0% | Chief Scientific Officer | |
May 6, 2026 | BLTE | Sell | 240 | $154.41 | $37K | −21.7% | Chief Scientific Officer | |
May 6, 2026 | BLTE | Sell | 8 | $151.57 | $1K | −0.5% | Chief Scientific Officer | |
May 6, 2026 | BLTE | Sell | 128 | $153.42 | $20K | −10.4% | Chief Scientific Officer | |
May 6, 2026 | BLTE | Sell | 100 | $155.97 | $16K | −11.5% | Chief Scientific Officer | |
May 6, 2026 | BLTE | Sell | 424 | $152.67 | $65K | −25.6% | Chief Scientific Officer | |
May 5, 2026 | BLTE | Sell | 121 | $156.53 | $19K | −6.0% | Chief Scientific Officer | |
May 5, 2026 | BLTE | Sell | 173 | $155.48 | $27K | −7.9% | Chief Scientific Officer | |
May 5, 2026 | BLTE | Sell | 68 | $158.11 | $11K | −3.9% | Chief Scientific Officer | |
May 5, 2026 | BLTE | Sell | 120 | $153.92 | $18K | −4.5% | Chief Scientific Officer | |
May 5, 2026 | BLTE | Sell | 363 | $154.44 | $56K | −14.3% | Chief Scientific Officer | |
May 5, 2026 | BLTE | Sell | 155 | $157.29 | $24K | −8.2% | Chief Scientific Officer | |
May 4, 2026 | BLTE | Sell | 236 | $154.24 | $36K | −6.5% | Chief Scientific Officer | |
May 4, 2026 | BLTE | Sell | 32 | $153.50 | $5K | −0.9% | Chief Scientific Officer | |
May 4, 2026 | BLTE | Sell | 172 | $157.49 | $27K | −6.1% | Chief Scientific Officer | |
May 4, 2026 | BLTE | Sell | 235 | $156.57 | $37K | −7.6% | Chief Scientific Officer | |
May 4, 2026 | BLTE | Sell | 325 | $155.21 | $50K | −9.6% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 52 | $153.89 | $8K | −1.1% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 23 | $160.00 | $4K | −0.6% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 82 | $156.24 | $13K | −2.1% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 38 | $159.08 | $6K | −1.0% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 65 | $158.35 | $10K | −1.7% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 106 | $157.45 | $17K | −2.7% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 346 | $155.48 | $54K | −8.0% | Chief Scientific Officer | |
May 1, 2026 | BLTE | Sell | 288 | $154.38 | $44K | −6.2% | Chief Scientific Officer | |
Apr 30, 2026 | BLTE | Sell | 340 | $157.37 | $54K | −6.7% | Chief Scientific Officer | |
Apr 30, 2026 | BLTE | Sell | 517 | $156.59 | $81K | −9.2% | Chief Scientific Officer | |
Apr 30, 2026 | BLTE | Sell | 101 | $158.15 | $16K | −2.1% | Chief Scientific Officer | |
Apr 30, 2026 | BLTE | Sell | 42 | $155.68 | $7K | −0.7% | Chief Scientific Officer | |
Apr 29, 2026 | BLTE | Sell | 339 | $156.43 | $53K | −5.5% | Chief Scientific Officer | |
Apr 29, 2026 | BLTE | Sell | 22 | $158.19 | $3K | −0.4% | Chief Scientific Officer | |
Apr 29, 2026 | BLTE | Sell | 259 | $155.52 | $40K | −4.1% | Chief Scientific Officer | |
Apr 29, 2026 | BLTE | Sell | 278 | $154.58 | $43K | −4.2% | Chief Scientific Officer | |
Apr 29, 2026 | BLTE | Sell | 102 | $157.39 | $16K | −1.8% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 120 | $160.27 | $19K | −1.7% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 89 | $161.72 | $14K | −1.3% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 53 | $156.61 | $8K | −0.7% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 380 | $159.42 | $61K | −5.2% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 62 | $158.71 | $10K | −0.8% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 222 | $157.49 | $35K | −2.9% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 8 | $155.36 | $1K | −0.1% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 12 | $154.65 | $2K | −0.2% | Chief Scientific Officer | |
Apr 28, 2026 | BLTE | Sell | 54 | $162.14 | $9K | −0.8% | Chief Scientific Officer | |
Apr 27, 2026 | BLTE | Sell | 409 | $163.56 | $67K | −5.0% | Chief Scientific Officer | |
Apr 27, 2026 | BLTE | Sell | 231 | $162.38 | $38K | −2.8% | Chief Scientific Officer | |
Apr 27, 2026 | BLTE | Sell | 280 | $161.62 | $45K | −3.2% | Chief Scientific Officer | |
Apr 27, 2026 | BLTE | Sell | 44 | $160.83 | $7K | −0.5% | Chief Scientific Officer |
Top Companies Traded
| TICKER | COMPANY | TRADES | TOTAL VOLUME |
|---|---|---|---|
| BLTE | BELITE BIO, INC | 102 | $2.7M |
Other insiders at BELITE BIO, INC
3 other tracked filers at BLTE.